Timing and Dose of Tissue Plasminogen Activator to Prevent Abscess Formation After Surgical Treatment of Secondary Peritonitis in the Rat

Early administration of fibrinolytics after surgical treatment of peritonitis in the rat reduces abscess formation. The current study investigates the effect of various treatment protocols using intraperitoneal recombinant tissue plasminogen activator (rtPA). Peritonitis was induced in rats and surgical debridement was performed after 1 hour. Animals were treated with rtPA at different time points. Abdominal fluid samples were taken at 24, 72, and 120 hours for cytokine measurements and cell counts. After 5 days the abdomen was inspected for abscesses. Early administration of rtPA significantly reduced the number of rats with abscesses and the abscess load per rat. Delayed treatment significantly reduced abscess load but not the incidence of abscesses. No meaningful differences in the local inflammatory response were found. rtPA was most effective when applied early and continued for 72 hours, although mortality increased after prolonged treatment. rtPA consistently reduces intra-abdominal abscess formation, and a clinical study seems warranted.

[1]  R. Bleichrodt,et al.  Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis. , 2009, Surgery.

[2]  R. Bleichrodt,et al.  Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis , 2008, The British journal of surgery.

[3]  R. Bleichrodt,et al.  Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. , 2008, Surgery.

[4]  M. Boermeester.  Surgical approaches to peritonitis , 2007, The British journal of surgery.

[5]  Helmut Küchenhoff,et al.  Secular trends in mortality associated with new therapeutic strategies in surgical critical illness. , 2007, American journal of surgery.

[6]  R. Bleichrodt,et al.  Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model , 2007, International Journal of Colorectal Disease.

[7]  R. Bleichrodt,et al.  A peritonitis model with low mortality and persisting intra‐abdominal abscesses , 2006, International journal of experimental pathology.

[8]  P. Carmeliet,et al.  Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia coli-Induced Abdominal Sepsis in Mice1 , 2006, The Journal of Immunology.

[9]  M. Perretti,et al.  Spatial and Temporal Profiles for Anti-Inflammatory Gene Expression in Leukocytes during a Resolving Model of Peritonitis1 , 2006, The Journal of Immunology.

[10]  E. Dellinger,et al.  Current treatment of intraabdominal infections. , 2005, Surgical technology international.

[11]  J. Marshall.  Intra-abdominal infections. , 2004, Microbes and infection.

[12]  M. Boermeester,et al.  Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis , 2004, The British journal of surgery.

[13]  B. Rau,et al.  Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis , 2004, Langenbeck's Archives of Surgery.

[14]  C. Sutton,et al.  Colo‐rectal anastomotic leakage often masquerades as a cardiac complication , 2004, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[15]  J. Marshall,et al.  Intensive care unit management of intra-abdominal infection , 2003, Critical care medicine.

[16]  D. Gouma,et al.  Meta‐analysis of relaparotomy for secondary peritonitis , 2002, The British journal of surgery.

[17]  E. Weiss,et al.  Percutaneous postoperative intra-abdominal abscess drainage after elective colorectal surgery , 2002, Techniques in Coloproctology.

[18]  M. Schein.  Surgical management of intra-abdominal infection: is there any evidence? , 2002, Langenbeck's Archives of Surgery.

[19]  W. Bell.  Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. , 2002, Reviews in cardiovascular medicine.

[20]  M. Jaff,et al.  Pharmacologic and clinical characteristics of thrombolytic agents. , 2002, Reviews in cardiovascular medicine.

[21]  K. Sirinek.  Diagnosis and treatment of intra-abdominal abscesses. , 2000, Surgical infections.

[22]  J. van der Meer,et al.  Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model. , 1996, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.

[23]  E. Faist,et al.  Update on the Mechanisms of Immune Suppression of Injury and Immune Modulation , 1996, World Journal of Surgery.

[24]  H. van Goor,et al.  Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator. , 1995, Journal of the American College of Surgeons.

[25]  J. van der Meer,et al.  Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. , 1994, Journal of the American College of Surgeons.

[26]  O. Rotstein,et al.  Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. , 1988, The Journal of infectious diseases.

[27]  A. Phuangsab,et al.  The effect of bacterial trapping by fibrin on the efficacy of systemic antibiotics in experimental peritonitis. , 1983, Surgery, gynecology & obstetrics.